New Option For Late-Stage Prostate Cancer

Dr. Crawford discusses Zytiga as a new option for late stage prostate cancer. Click here to learn more

Recent Posts

Dr(s) David Crawford and Marc Garnick discuss the new 2017 USPSTF recommendations and how this impacts PSA screening. Click here to learn...

Dr. Crawford discusses the TERRAIN and STRIVE studies and their impact on castrate resistant prostate cancer. Click here to learn more.

Dr. Crawford discusses the surprising trend of how there is a decline in prostate cancer screening amongst primary care docs. Click here...